According to a Bursa Malaysia filing, the lesser net profit was due to the lower production by Pharmaniaga
KUALA LUMPUR: Pharmaniaga Bhd
will be collaborating with Pharco Pharmaceuticals and the Drugs for Neglected Diseases Initiative in an effort to promote affordable access to drug treatment of Hepatitis C in Malaysia.
Pharco Pharmaceuticals is a leading pharmaceutical distributor in Egypt, the Middle East and Africa while the Drugs for Neglected Diseases Initiative is a Swiss-based non-profit organisation that conducts research and development on drug treatment of neglected diseases.
According to a filing with Bursa Malaysia, Pharmaniaga unit Pharmaniaga Logistics Sdn Bhd entered into an agreement with the two parties to "promote widespread access to affordable direct acting antivirals (DAAs) including ravidasvir in combination with sofosbuvir or other potential DAAs as safe, effective, affordable and pan-genotypic treatments for Hepatitis C in Malaysia".
At 12.30pm, Pharmaniaga was trading unchanged at RM4 on low volume of shares traded.
Limited time offer:
Just RM5 per month.
